IL163898A0 - Combination of an aldosterone receptor antagonist and a fibric acid derivative - Google Patents
Combination of an aldosterone receptor antagonist and a fibric acid derivativeInfo
- Publication number
- IL163898A0 IL163898A0 IL16389803A IL16389803A IL163898A0 IL 163898 A0 IL163898 A0 IL 163898A0 IL 16389803 A IL16389803 A IL 16389803A IL 16389803 A IL16389803 A IL 16389803A IL 163898 A0 IL163898 A0 IL 163898A0
- Authority
- IL
- Israel
- Prior art keywords
- combination
- acid derivative
- receptor antagonist
- aldosterone receptor
- fibric acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36524202P | 2002-03-18 | 2002-03-18 | |
| PCT/US2003/008206 WO2003080118A2 (en) | 2002-03-18 | 2003-03-18 | Combination of an aldosterone receptor antagonist and a fibric acid derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL163898A0 true IL163898A0 (en) | 2005-12-18 |
Family
ID=28454632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16389803A IL163898A0 (en) | 2002-03-18 | 2003-03-18 | Combination of an aldosterone receptor antagonist and a fibric acid derivative |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1485132A2 (es) |
| JP (1) | JP2005523302A (es) |
| KR (1) | KR20040107482A (es) |
| CN (1) | CN1642573A (es) |
| AU (1) | AU2003223287A1 (es) |
| BR (1) | BR0308494A (es) |
| CA (1) | CA2479722A1 (es) |
| IL (1) | IL163898A0 (es) |
| MX (1) | MXPA04009032A (es) |
| PL (1) | PL372588A1 (es) |
| WO (1) | WO2003080118A2 (es) |
| ZA (1) | ZA200407462B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101286743B1 (ko) * | 2011-02-18 | 2013-07-15 | 충남대학교산학협력단 | 페노피브레이트를 함유하는 패혈증 예방용 약학 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000038725A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations for cardiovascular indications |
| EP1299385A2 (en) * | 2000-06-28 | 2003-04-09 | Bristol-Myers Squibb Company | Fused cyclic modulators of nuclear hormone receptor function |
| CA2420055C (en) * | 2000-08-25 | 2010-06-01 | Takeda Chemical Industries, Ltd. | Fibrinogen-lowering agent |
-
2003
- 2003-03-18 WO PCT/US2003/008206 patent/WO2003080118A2/en not_active Application Discontinuation
- 2003-03-18 JP JP2003577943A patent/JP2005523302A/ja not_active Withdrawn
- 2003-03-18 IL IL16389803A patent/IL163898A0/xx unknown
- 2003-03-18 CA CA002479722A patent/CA2479722A1/en not_active Abandoned
- 2003-03-18 EP EP03719400A patent/EP1485132A2/en not_active Withdrawn
- 2003-03-18 BR BR0308494-9A patent/BR0308494A/pt not_active IP Right Cessation
- 2003-03-18 AU AU2003223287A patent/AU2003223287A1/en not_active Abandoned
- 2003-03-18 PL PL03372588A patent/PL372588A1/xx not_active Application Discontinuation
- 2003-03-18 CN CNA03806300XA patent/CN1642573A/zh active Pending
- 2003-03-18 KR KR10-2004-7014574A patent/KR20040107482A/ko not_active Application Discontinuation
- 2003-03-18 MX MXPA04009032A patent/MXPA04009032A/es not_active Application Discontinuation
-
2004
- 2004-09-16 ZA ZA200407462A patent/ZA200407462B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005523302A (ja) | 2005-08-04 |
| WO2003080118A2 (en) | 2003-10-02 |
| BR0308494A (pt) | 2005-05-03 |
| KR20040107482A (ko) | 2004-12-20 |
| WO2003080118A3 (en) | 2004-01-15 |
| CN1642573A (zh) | 2005-07-20 |
| CA2479722A1 (en) | 2003-10-02 |
| ZA200407462B (en) | 2006-07-26 |
| EP1485132A2 (en) | 2004-12-15 |
| PL372588A1 (en) | 2005-07-25 |
| MXPA04009032A (es) | 2005-01-25 |
| AU2003223287A1 (en) | 2003-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236190A0 (en) | Controlled release of anti-infections | |
| AU2003243497A8 (en) | Antagonists of melanin concentrating hormone receptor | |
| EP1605892A4 (en) | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND AN ANTI-DIABETIC AGENT | |
| HK1156626A1 (en) | Stable hydrate of a muscarinic receptor antagonist | |
| SI2065384T1 (sl) | Tricikliäśni trombin receptor antagonist | |
| EP1653960A4 (en) | MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST | |
| HK1073304A1 (en) | Triazole derivatives as tachykinin receptor antagonists | |
| IL165871A0 (en) | Substituted quinoline CCR5 receptor antagonists | |
| AU2003275128A8 (en) | Isolation and use of ryanodine receptors | |
| EP1550818A4 (en) | SHOCK ABSORBER FIXATION STRUCTURE | |
| EG23458A (en) | Set of elements for assemlying structures | |
| MY143499A (en) | Crf receptor antagonist and methods relating thereto | |
| IL164016A0 (en) | Azetidine derivatives as ccr-3 receptor antagonists | |
| PL373032A1 (en) | Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative | |
| AU2003267088A1 (en) | Chemokine receptor antagonists as therapeutic agents | |
| AU2003279841A8 (en) | Uses of human zven antagonists | |
| AU2003260072A8 (en) | Antagonists of chemokine receptors | |
| AU2003300904A8 (en) | Antagonists for human prolactin | |
| AU2003240705A1 (en) | Morpholinylmethylureas ccr-3 receptor antagonists | |
| EP1570860A4 (en) | ANTAGONIST AND AGONIST BINDING TO A STRONG BINDING SITE OF THE CHEMOKINE RECEPTOR | |
| IL163898A0 (en) | Combination of an aldosterone receptor antagonist and a fibric acid derivative | |
| IL163893A0 (en) | Combination of an aldosterone receptor antagonist and a bile acid sequestering agent | |
| IL161521A0 (en) | N-formyl derivatives of paroxetine | |
| IL160438A0 (en) | Pharmaceutical compositions containing an angiotensin ii receptor antagonist | |
| AU2003223329A8 (en) | Antagonists of rf-amide neuropeptides |